Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S, Kitazono S, Tanaka H, Saito R, Kawashima Y, Ohyanagi F, Tozuka T, Ryosuke T, Sakatani T, Horiike A, Yoshizawa T, Saiki M, Tambo Y, Koyama J, Kanazu M, Kudo K, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Uematsu S, et al. Among authors: ohyanagi f. Thorac Cancer. 2023 Jan;14(2):168-176. doi: 10.1111/1759-7714.14729. Epub 2022 Nov 21. Thorac Cancer. 2023. PMID: 36408699 Free PMC article.
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).
Tanaka H, Sakamoto H, Akita T, Ohyanagi F, Kawashima Y, Tambo Y, Tanimoto A, Horiike A, Miyauchi E, Tsuchiya-Kawano Y, Yanagitani N, Nishio M. Tanaka H, et al. Among authors: ohyanagi f. Thorac Cancer. 2022 May;13(10):1471-1478. doi: 10.1111/1759-7714.14415. Epub 2022 Apr 12. Thorac Cancer. 2022. PMID: 35415873 Free PMC article.
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Sakai K, Horiike A, Irwin DL, Kudo K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Sakai K, et al. Among authors: ohyanagi f. Cancer Sci. 2013 Sep;104(9):1198-204. doi: 10.1111/cas.12211. Epub 2013 Jul 1. Cancer Sci. 2013. PMID: 23721103 Free PMC article.
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Horiike A, Takeuchi K, Uenami T, Kawano Y, Tanimoto A, Kaburaki K, Tambo Y, Kudo K, Yanagitani N, Ohyanagi F, Motoi N, Ishikawa Y, Horai T, Nishio M. Horiike A, et al. Among authors: ohyanagi f. Lung Cancer. 2016 Mar;93:43-6. doi: 10.1016/j.lungcan.2015.12.011. Epub 2015 Dec 30. Lung Cancer. 2016. PMID: 26898613
55 results